Arrowhead Pharmaceuticals, Inc. (ARWR): A bull case theory

We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...

Chiefs’ Kansas Move Leaves Missouri With a $150 Million Arrowhead Problem

Arrowhead Stadium could cost Missouri $150 million to demolish after the Chiefs move to Kansas, leaving officials with a ...

Past results don’t assure future success: Arrowhead’s history is cautionary tale

The state of Kansas is willing to spend billions on the Chiefs, the “it” team of the recent past. But what happens if the ...

Arrowhead gains as obesity therapy doubles weight loss with Lilly’s Zepbound

Arrowhead Pharma (ARWR) stock jumps as obesity drug ARO-INHBE doubles weight loss with Eli Lilly’s (LLY) GLP-1 therapy, tirzepatide in a Phase 1/2 trial. Read more here.
BioSpace

Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and enhance weight loss as compared to tirzepatide alone, particularly in patients ...
STAT

Arrowhead’s gene-silencing drugs cut fat in early obesity studies

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing candidates helped people with obesity lose fat.